Black Diamond ended the second quarter of 2023 with approximately $89.5 million in cash, cash equivalents and investments. The Company believes that the net proceeds from the Follow-on Offering, together with its existing cash, cash equivalents and investments, will enable the Company to fund its operating expenses and capital expenditure requirements into the first half of 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BDTX:
- Black Diamond Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- TipRanks’ ‘Perfect 10’ List: These Monster Growth Stocks Could Reach New Highs
- Piper starts Black Diamond at Overweight on ‘clear opportunity’
- Black Diamond Therapeutics initiated with an Overweight at Piper Sandler
- Fly Insider: Children’s Place, Netflix among notable insider trades this week
